Alnylam
‘CRISPR this, CRISPR that’: Is our fascination with the popular gene-editing tool distracting us from the potential of gene-silencing RNAi technology?
I hope the public fascination with CRISPR can also embrace the other biotechnologies providing new therapeutic options ...
Second RNAi-based drug gains FDA approval, targeting rare genetic condition causing severe abdominal pain
The FDA has approved the second-ever drug based on a Nobel prize-winning technique known as RNA interference, Alnylam’s givosiran. The ...
